Atara Biotherapeutics, Inc. — Investor Relations & Filings

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company that develops off-the-shelf treatments for patients with cancer and autoimmune diseases. The company leverages its proprietary Epstein-Barr virus (EBV) T-cell platform and novel chimeric antigen receptor (CAR) technologies to create a pipeline of investigational therapies. Its allogeneic approach enables the manufacturing of T-cell therapies from healthy donors, which can be stored in inventory and rapidly delivered to patients. Atara is the first company to receive regulatory approval for an allogeneic T-cell immunotherapy, utilizing a scalable manufacturing process and a versatile platform with potential applications for a wide range of disease targets.